Cue Biopharma Inc
CUE
Get informed when a big investor buys or sells
+ FollowMarket Cap$71.27M
Close$
$-0.76
102.5% downside
Current Fair Value
102.5% downsideOvervalued by 102.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $71.27 Million |
|---|---|
| Enterprise Value | $58.33 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.4 |
| Beta | 2.46 |
| Outstanding Shares | 4,807,494 |
Return
| Return on Equity | -90.35% |
|---|---|
| Return on Assets | -63.23% |
| Return on Invested Capital | -84.07% |
Valuation & Multiples
| P/E Ratio | -4.91 |
|---|---|
| PEG | 8.51 |
| Price to Sales | 5.07 |
| Price to Book Ratio | 7.61 |
| Enterprise Value to Revenue | 1.78 |
| Enterprise Value to EBIT | -2.95 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-3.30
Average shareholder expectationRevenue Estimate
$2.50 M
Average shareholder expectationNext Earnings Call
Expected Date
August 18, 2026
EPS Estimate
$-1.69
Average shareholder expectationRevenue Estimate
$3.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 34,900▲ Infinity% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.33%▼ 12.50% |
|---|---|
| Total Invested | $3.53M▼ 28.69% |
| Investors Holding | 14▼ 40.00% |
ESG Score
No data
About Cue Biopharma Inc
CEO: Daniel Passeri